3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
3
Small Cell Lung Carcinoma
2
Gliosarcoma
2
Glioblastoma
2
Carcinoma, Ovarian Epithelial
2
Carcinoma, Non-Small-Cell Lung
2
Astrocytoma
2
Waldenstrom Macroglobulinemia
1
Squamous Cell Carcinoma of Head and Neck
1
Sezary Syndrome
1
Recurrence
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Oropharyngeal Neoplasms
1
Oligodendroglioma
1
Neoplasm Metastasis
1
Mycosis Fungoides
1
Multiple Myeloma
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, T-Cell
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, Extranodal NK-T-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
Dexamethasone
33
Cyclophosphamide
29
venetoclax
18
fludarabine
18
Lenalidomide
16
Bortezomib
16
Cytarabine
13
pembrolizumab
12
Calcium Dobesilate
12
Carboplatin
11
fludarabine phosphate
10
Rituximab
10
pomalidomide
9
Gemcitabine
9
Nivolumab
8
Azacitidine
7
daratumumab
6
carfilzomib
6
blinatumomab
6
Decitabine
6
Bendamustine Hydrochloride
6
selinexor
5
obinutuzumab
5
ibrutinib
5
Vincristine
5
Temozolomide
5
Methotrexate
5
Etoposide
5
Cisplatin
5
tafasitamab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Recurrence
×
veliparib
×
Clear all
NCT01472783
2016-11-16
Veli-BRCA
Vejle Hospital
Phase 1/2
Completed
49 enrolled